Recruiting EARLY_PHASE1 INTERVENTIONAL 1-arm NCT06639191

[177Lu]Lu-AKIR001 First-in-human Study (AKIR001)

A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours

Sponsor: Karolinska Institutet

Conditions Cancer Head and Neck Cervix Carcinoma Non-small Cell Lung Cancer Stage IV Poorly Differentiated Thyroid Carcinoma Thyroid Gland Anaplastic Carcinoma Vulvar Cancer, Stage IV

Interventions [177Lu]Lu-AKIR001

Updated 2 times since 2024 Last updated: Jan 28, 2026 Started: Jan 28, 2026 Primary completion: Nov 1, 2027 Completion: Nov 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06639191, this EARLY_PHASE1 trial focuses on Cancer Head and Neck and Cervix Carcinoma and remains actively recruiting participants. Sponsored by Karolinska Institutet, it has been updated 2 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting
Nov 2024 — Feb 2026 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Karolinska Institutet
Karolinska University Hospital
Uppsala University

Data source: Karolinska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden